LMIR1, also termed CD300a, is a type I transmembrane glycoprotein with a single IgV-like extracellular domain and an extended membrane proximal region that links the immunoglobulin (Ig) and transmembrane domains and belongs to the immunoglobulin superfamily. The intracellular domain of LMIR1 contains several immunoreceptor tyrosine-based inhibition motifs (ITIMs). When cross-linked, it will be tyrosine phosphorylated and capable of recruiting tyrosine phosphatases (SHP-1, SHP-2) and inositol polyphosphate 5-phosphatase, SHIP. LMIR1 will regulate mast cell-mediated inflammatory responses. LMIR1 is broadly expressed on myeloid and lymphoid cells, and its expression is differentially regulated depending on the cell type.
Product Name:
Mouse CD300a/LMIR1 Recombinant Protein (RPES2106)
Product Code:
RPES2106
Size:
10µg
Species:
Mouse
Expressed Host:
Human Cells
Synonyms:
CD300a,CD300a antigen,CMRF35H9, CD300a molecule, leukocyte immunoglobulin-like receptor,CD300 antigen-like family member A, CMRF35-like molecule 8,NK inhibitory receptor, Immunoglobulin superfamily member 12, IRp60,Inhibitory receptor protein 60, CLM8, CMRF-35H, IGSF12, IRC1, IRC2, LMIR1,CLM-8,MAIR-I,Clm8,MAIR-I,MAIR-Ia,mcpir1,MMAC8,Pigr4
Accession:
Q6SJQ0
Sequence:
Leu28-Arg183
Fusion tag:
C-Fc
Endotoxin:
<1.0 EU per µg as determined by the LAL method.
Protein Construction:
Recombinant Mouse Leukocyte mono-Ig-like receptor 1 is produced by our Mammalian expression system and the target gene encoding Leu28-Arg183 is expressed with a Fc tag at the C-terminus.
Purity:
> 95 % as determined by SDS-PAGE
Mol Mass:
44.3 kDa
AP Mol Mass:
58-75 kDa
Formulation:
Lyophilized from a 0.2 µm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.
Shipping:
This product is provided as lyophilized powder which is shipped with ice packs.
Stability and Storage:
Lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
